StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.81 | $3.88 | +1.84% | 1.1M |
| 05-12 | $4.06 | $3.77 | -7.14% | 1.3M |
| 05-13 | $3.79 | $3.82 | +0.79% | 1.0M |
| 05-14 | $3.85 | $3.86 | +0.26% | 0.8M |
| 05-15 | $3.85 | $3.85 | +0.00% | 0.9M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 | Q2 2023 2023-06-30 | Q1 2023 2023-03-31 |
|---|---|---|---|---|
Revenue | $1.43M | $5.24M | $3.33M | $1.83M |
Operating Income | $-40.94M | $-29.27M | $-19.52M | $-9.76M |
Net Income | $-46.51M | $-21.83M | $-11.11M | $-371.00K |
EPS (Diluted) | $-1.74 | $-0.83 | $-0.45 | $0.00 |
Total Assets | $97.89M | $110.52M | $120.14M | $127.64M |
Total Liabilities | $22.71M | $11.75M | $11.49M | $9.62M |
Cash & Equivalents | $9.24M | $17.98M | $28.32M | $36.45M |
Free Cash Flow OCF − CapEx | $-37.98M | $-28.89M | $-18.55M | $-9.92M |
Shares Outstanding | 28.18M | 280.57M | 280.48M | 278.66M |